EBSWORTH DAVID R

Director Ebsworth buys 20,000 shares of VRNA at $4.44 on 2024-11-18; repeats pattern after Nov 6 buy with strong prior track record at this ticker.

Director David R Ebsworth purchased 20,000 shares at $4.44 on 2024-11-18, just 12 days after a prior $4.44 buy on 2024-11-06, signaling sustained commitment at the current level. At this ticker, Ebsworth's prior two measurable buys (August 2024 and November 2023) delivered +950.5% and +574.8% 30-day returns respectively, establishing a 2-of-2 pattern of well-timed purchases. His cross-ticker track record shows 3 prior buys with an average 90-day return of +1035.6% and a 100.00% 90-day win rate. Stock currently trades at $34.94, down 12.4% from the 52-week high of $39.87 but up 27.2% over the past 90 days. The company is unprofitable (net income $-43.0M over the latest full fiscal year) with quarterly revenue of only $5.6M, placing this within a high-risk, development-stage biotech profile where insider conviction decisions carry added weight.

Director David Ebsworth buys 39,360 shares of VRNA at $4.80; stock now $38.18, +68.8% in 90 days.

Director Ebsworth purchased 39,360 shares at $4.80 on 2024-11-06, increasing his holdings to 920,003 shares post-transaction. The stock has appreciated significantly since purchase, trading at $38.18 and reflecting a +68.8% gain over the prior 90 days. His prior buy at this ticker on 2024-08-12 achieved a +950.5% 30-day return, and his earlier VRNA purchase on 2023-11-06 delivered +826.8% over 90 days, establishing a pattern of well-timed accumulation at this ticker. However, the underlying business remains unprofitable with a net loss of $-43.0M in the latest period and zero annual revenue growth (FY -100.0%), creating tension between strong price momentum and deteriorating fundamentals. Investors should assess whether the recent price strength reflects genuine clinical progress or market exuberance ahead of potential catalysts, while monitoring the company's path to cash flow sustainability given its current burn rate.

Director Ebsworth bought 36,000 VRNA shares at $2.87 on 2024-08-12; stock now at $27.31, up 104.4% in 90 days.

David R Ebsworth, a director at Verona Pharma, purchased 36,000 shares at $2.87 on 2024-08-12, increasing his holdings to 880,643 shares. The timing of this purchase proved exceptionally well-calibrated: the stock has appreciated 104.4% over the subsequent 90 days and now trades at $27.31, near its 52-week high. This pattern aligns with Ebsworth's cross-ticker track record, where his prior open-market purchases have averaged +826.8% 90-day returns with a 100.00% win rate. However, context is critical—Verona Pharma reported $0.00 revenue in its latest quarter and a net loss of $-70,835,000.00, reflecting an unprofitable biotech development stage. The director's buy signal emerges in a deeply challenged fundamental backdrop, suggesting conviction in future value rather than response to current earnings or operational performance.